Cargando…
In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up
Paclitaxel and trastuzumab have been associated with adverse effects including chemotherapy-induced peripheral neuropathy (CIPN) or ocular complications. In vivo confocal laser scanning microscopy (CLSM) of the cornea could be suitable for assessing side effects since the cornea is susceptible to, i...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139605/ https://www.ncbi.nlm.nih.gov/pubmed/35626335 http://dx.doi.org/10.3390/diagnostics12051180 |
_version_ | 1784714898359451648 |
---|---|
author | Bohn, Sebastian Stache, Nadine Sperlich, Karsten Allgeier, Stephan Köhler, Bernd Bartschat, Andreas Do, Ha-Vy George, Christian Guthoff, Rudolf F. Stachs, Angrit Stachs, Oliver Sterenczak, Katharina Anna |
author_facet | Bohn, Sebastian Stache, Nadine Sperlich, Karsten Allgeier, Stephan Köhler, Bernd Bartschat, Andreas Do, Ha-Vy George, Christian Guthoff, Rudolf F. Stachs, Angrit Stachs, Oliver Sterenczak, Katharina Anna |
author_sort | Bohn, Sebastian |
collection | PubMed |
description | Paclitaxel and trastuzumab have been associated with adverse effects including chemotherapy-induced peripheral neuropathy (CIPN) or ocular complications. In vivo confocal laser scanning microscopy (CLSM) of the cornea could be suitable for assessing side effects since the cornea is susceptible to, i.e., neurotoxic stimuli. The study represents a one-year follow-up of a breast cancer patient including large-area in vivo CLSM of the subbasal nerve plexus (SNP), nerve function testing, and questionnaires during paclitaxel and trastuzumab therapy. Six monitoring sessions (one baseline, four during, and one after therapy) over 58 weeks were carried out. Large-area mosaics of the SNP were generated, and identical regions within all sessions were assigned. While corneal nerve morphology did not cause alterations, the number of dendritic cells (DCs) showed dynamic changes with a local burst at 11 weeks after baseline. Simultaneously, paclitaxel treatment was terminated due to side effects, which, together with DCs, returned to normal levels as the therapy progressed. Longitudinal in vivo CLSM of the SNP could complement routine examinations and be helpful to generate a comprehensive clinical picture. The applied techniques, with corneal structures acting as biomarkers could represent a diagnostic tool for the objective assessment of the severity of adverse events and the outcome. |
format | Online Article Text |
id | pubmed-9139605 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91396052022-05-28 In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up Bohn, Sebastian Stache, Nadine Sperlich, Karsten Allgeier, Stephan Köhler, Bernd Bartschat, Andreas Do, Ha-Vy George, Christian Guthoff, Rudolf F. Stachs, Angrit Stachs, Oliver Sterenczak, Katharina Anna Diagnostics (Basel) Interesting Images Paclitaxel and trastuzumab have been associated with adverse effects including chemotherapy-induced peripheral neuropathy (CIPN) or ocular complications. In vivo confocal laser scanning microscopy (CLSM) of the cornea could be suitable for assessing side effects since the cornea is susceptible to, i.e., neurotoxic stimuli. The study represents a one-year follow-up of a breast cancer patient including large-area in vivo CLSM of the subbasal nerve plexus (SNP), nerve function testing, and questionnaires during paclitaxel and trastuzumab therapy. Six monitoring sessions (one baseline, four during, and one after therapy) over 58 weeks were carried out. Large-area mosaics of the SNP were generated, and identical regions within all sessions were assigned. While corneal nerve morphology did not cause alterations, the number of dendritic cells (DCs) showed dynamic changes with a local burst at 11 weeks after baseline. Simultaneously, paclitaxel treatment was terminated due to side effects, which, together with DCs, returned to normal levels as the therapy progressed. Longitudinal in vivo CLSM of the SNP could complement routine examinations and be helpful to generate a comprehensive clinical picture. The applied techniques, with corneal structures acting as biomarkers could represent a diagnostic tool for the objective assessment of the severity of adverse events and the outcome. MDPI 2022-05-09 /pmc/articles/PMC9139605/ /pubmed/35626335 http://dx.doi.org/10.3390/diagnostics12051180 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Interesting Images Bohn, Sebastian Stache, Nadine Sperlich, Karsten Allgeier, Stephan Köhler, Bernd Bartschat, Andreas Do, Ha-Vy George, Christian Guthoff, Rudolf F. Stachs, Angrit Stachs, Oliver Sterenczak, Katharina Anna In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up |
title | In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up |
title_full | In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up |
title_fullStr | In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up |
title_full_unstemmed | In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up |
title_short | In Vivo Monitoring of Corneal Dendritic Cells in the Subbasal Nerve Plexus during Trastuzumab and Paclitaxel Breast Cancer Therapy—A One-Year Follow-Up |
title_sort | in vivo monitoring of corneal dendritic cells in the subbasal nerve plexus during trastuzumab and paclitaxel breast cancer therapy—a one-year follow-up |
topic | Interesting Images |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139605/ https://www.ncbi.nlm.nih.gov/pubmed/35626335 http://dx.doi.org/10.3390/diagnostics12051180 |
work_keys_str_mv | AT bohnsebastian invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT stachenadine invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT sperlichkarsten invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT allgeierstephan invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT kohlerbernd invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT bartschatandreas invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT dohavy invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT georgechristian invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT guthoffrudolff invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT stachsangrit invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT stachsoliver invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup AT sterenczakkatharinaanna invivomonitoringofcornealdendriticcellsinthesubbasalnerveplexusduringtrastuzumabandpaclitaxelbreastcancertherapyaoneyearfollowup |